Statera BioPharma (FRA:7CB) Forward PE Ratio: 0.00 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7CB Statera BioPharma Inc FRA:7CB
20 GF Score
Price €2.61
View Full Analysis

What is Statera BioPharma Forward PE Ratio?

Statera BioPharma FRA:7CB 20 Forward PE Ratio is 0.00 as of Jul. 21, 2026. GuruFocus rates FRA:7CB with a GF Score™ of 20/100.

Statera BioPharma's Forward PE Ratio for today is 0.00.

Statera BioPharma's PE Ratio without NRI for today is 0.00.

Statera BioPharma's PE Ratio (TTM) for today is 0.00.

Statera BioPharma  (FRA:7CB) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Statera BioPharma Forward PE Ratio Related Terms

Statera BioPharma Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Forward PE Ratio Chart

Statera BioPharma Annual Data
Trend
Forward PE Ratio

Statera BioPharma Quarterly Data
Forward PE Ratio

FRA:7CB vs NRBO, PALI, BLCM: Forward PE Ratio Comparison

For the Biotechnology subindustry, Statera BioPharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Statera BioPharma Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Forward PE Ratio falls into.


FRA:7CB
20GF Score
Statera BioPharma Inc FRA:7CB
Forward PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Statera BioPharma Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
Statera BioPharma (FRA:7CB) has a Forward PE Ratio of 0.00 as of Jul. 21, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's Forward PE Ratio too high?
Statera BioPharma's current Forward PE Ratio is 0.00. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's Forward PE Ratio compare to NRBO and PALI?
Statera BioPharma's Forward PE Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median Forward PE Ratio is 22.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.24, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Statera BioPharma and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Statera BioPharma's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (FRA:7CB) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Statera BioPharma's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Statera BioPharma (FRA:7CB), the current Forward PE Ratio is 0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.
20GF Score

Get the complete analysis for FRA:7CB

Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.61
Price